Medical Pharmacology Question Bank

Chapter 2: Pharmacokinetics — Module 1: Membrane Transport, Absorption, and Bioavailability
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions establish the pharmacokinetic framework for drug absorption and bioavailability — the principles that govern how much of an administered drug actually reaches the systemic circulation and how fast. You will work through questions on membrane structure and the factors determining passive diffusion, the Henderson-Hasselbalch relationship and pH-dependent ionization, active and facilitated transport mechanisms, P-glycoprotein efflux, routes of administration and their pharmacokinetic implications, first-pass hepatic extraction, oral bioavailability calculation from AUC data, bioequivalence standards, and the clinical consequences of hepatic disease on bioavailability. Several questions require quantitative reasoning — dose conversion between routes, bioavailability calculation, and the clinical implications of altered first-pass extraction. Work through each question before reading the rationale.

1. The cell membrane presents the primary structural barrier to drug absorption. Which of the following correctly describes the feature of membrane architecture most relevant to passive drug transport?

A) The membrane consists of a dynamic phospholipid bilayer with a hydrophobic lipid core — lipophilic un-ionized molecules dissolve into and traverse this core freely, while polar and ionized molecules are excluded unless specific transporters are present
B) The membrane is a rigid crystalline lattice of phospholipids that permits drug passage only through fixed protein channels sized for specific molecular weights
C) The membrane is predominantly composed of cholesterol, which forms aqueous pores large enough for any drug molecule below 500 daltons to pass by simple diffusion regardless of ionization state
D) The membrane presents no meaningful barrier to small drug molecules because all compounds below 300 daltons diffuse freely through the phospholipid bilayer regardless of charge or lipophilicity
E) The membrane is selectively permeable only to endogenous molecules — exogenous drugs require active transport regardless of their physicochemical properties because the bilayer evolved to exclude foreign compounds

ANSWER: A

Rationale:

The fluid mosaic model describes the cell membrane as a dynamic phospholipid bilayer in which polar phosphate head groups face outward toward aqueous environments on each side while nonpolar fatty acid tails face inward, creating a hydrophobic core. This architecture is the central determinant of passive drug transport: lipophilic, un-ionized molecules dissolve readily into the hydrophobic interior and diffuse across the membrane along their concentration gradient without requiring energy or carrier proteins. Polar, ionized, or large hydrophilic molecules cannot partition into the lipid core and are therefore excluded from passive diffusion — they require specific transport proteins to cross the membrane. The clinical implication is that the physicochemical properties of a drug — particularly its lipophilicity (logP) and its ionization state at physiological pH — are primary determinants of membrane permeability and therefore of absorption, distribution into tissues, and access to intracellular targets.

2. The ionization state of a weak acid or weak base drug at a given pH is determined by the Henderson-Hasselbalch relationship. Which of the following correctly applies this principle to drug absorption?

A) Weak acid drugs are predominantly ionized in the acidic environment of the stomach (pH 1-2) and are therefore well absorbed there, while weak bases are poorly absorbed in the stomach because they remain un-ionized and membrane-impermeable at low pH
B) Weak acid drugs are predominantly un-ionized in the acidic stomach environment and are therefore more membrane-permeable and better absorbed there, while weak bases are predominantly ionized in the stomach and less well absorbed — the opposite pattern holds in the alkaline small intestine
C) Ionization state has no clinically meaningful effect on drug absorption because modern drug formulations use enteric coatings to bypass pH-dependent absorption differences entirely
D) All drugs are fully ionized at physiological pH values and therefore depend entirely on active transport systems for membrane permeation — passive diffusion does not contribute to drug absorption in any clinically meaningful way
E) Weak bases are better absorbed in the acidic stomach because lower pH drives protonation, which increases lipophilicity and membrane permeability — the opposite of what occurs with weak acids

ANSWER: B

Rationale:

The Henderson-Hasselbalch equation predicts the ratio of ionized to un-ionized drug as a function of pH and pKa. For a weak acid, when environmental pH is below the drug's pKa, the un-ionized form predominates — the acid retains its proton and is electrically neutral, lipophilic, and membrane-permeable. In the acidic stomach (pH 1-2), most weak acid drugs (pKa typically 3-5) are predominantly un-ionized and therefore passively absorbed across the gastric epithelium. As pH rises in the small intestine, the weak acid becomes increasingly ionized, reducing passive permeability — though the large absorptive surface area of the small intestine means significant absorption still occurs there. The opposite pattern applies to weak bases: in the acidic stomach the base accepts a proton and becomes positively charged (ionized), reducing membrane permeability; in the more alkaline small intestine (pH 6-7), the weak base loses its proton, becomes un-ionized, and is better absorbed. This pH-partitioning principle also underlies therapeutic maneuvers such as urine alkalinization to trap weak acid drugs in the renal tubule and accelerate their excretion in overdose.

3. Several membrane transport mechanisms contribute to drug absorption beyond simple passive diffusion. Which of the following correctly distinguishes active transport from passive diffusion in the context of drug absorption?

A) Active transport moves drug down its concentration gradient without energy expenditure, while passive diffusion moves drug against its concentration gradient using ATP-dependent pumps — both mechanisms are saturable and subject to competitive inhibition
B) Active transport uses energy (typically ATP hydrolysis) to move drug molecules against their electrochemical gradient via specific carrier proteins — it is saturable, subject to competitive inhibition, and can concentrate drug on one side of a membrane; passive diffusion requires no energy, is not saturable, and moves drug down its concentration gradient only
C) Active transport and passive diffusion are functionally equivalent for most drugs — the distinction matters only for macromolecules above 1000 daltons where passive diffusion becomes physically impossible through the lipid bilayer
D) Active transport is the dominant mechanism for all orally absorbed drugs because passive diffusion is too slow to produce meaningful plasma concentrations within the time frame of gastrointestinal transit
E) Active transport moves drug in the absorptive direction only (lumen to blood), while passive diffusion is bidirectional — efflux transporters such as P-glycoprotein represent a subtype of passive diffusion operating in the secretory direction

ANSWER: B

Rationale:

Active transport is mediated by specific membrane carrier proteins that use metabolic energy — most commonly ATP hydrolysis via ABC transporters, or ion gradients via SLC transporters — to move drug molecules against their electrochemical concentration gradient. Because the process depends on a finite number of carrier molecules, it is saturable (follows Michaelis-Menten kinetics), subject to competitive inhibition by other substrates or inhibitors of the same transporter, and capable of concentrating drug on one side of a membrane far beyond levels achievable by diffusion. Passive diffusion, by contrast, requires no energy, uses no carrier protein, is not saturable, and can only move drug from higher to lower concentration — it will eventually reach equilibrium. Both mechanisms contribute to oral drug absorption: passive diffusion dominates for lipophilic drugs, while active uptake transporters (such as OATP1B1 in hepatocytes or peptide transporters in the gut) are important for specific hydrophilic drugs. Efflux transporters such as P-glycoprotein are a form of active transport operating in the secretory direction — they actively pump drug out of epithelial cells back into the gut lumen, opposing absorption and reducing oral bioavailability for their substrates.

4. P-glycoprotein (P-gp) is an efflux transporter expressed at multiple anatomical sites including the intestinal epithelium, the blood-brain barrier, renal tubular cells, and hepatocytes. Which of the following best describes P-gp's clinical significance for drug pharmacokinetics?

A) P-gp is a passive diffusion channel that enhances absorption of hydrophilic drugs by creating aqueous conduits through epithelial cell membranes — inhibition of P-gp reduces absorption of hydrophilic compounds
B) P-gp is an influx transporter that concentrates drugs inside epithelial cells — induction of P-gp by rifampin increases intracellular drug concentrations and enhances pharmacological effect at target tissues
C) P-gp is an inducible, ATP-dependent efflux pump that actively transports substrate drugs out of cells back into the gut lumen, blood, or bile — it limits oral bioavailability, restricts CNS penetration, and mediates clinically significant drug interactions when induced or inhibited
D) P-gp expression is limited to the intestinal epithelium — its only pharmacokinetic role is reducing oral bioavailability, and it has no influence on drug distribution into the CNS or elimination by the liver and kidney
E) P-gp substrate drugs are always poorly absorbed orally and must be administered intravenously — no P-gp substrate has achieved clinically useful oral bioavailability despite pharmaceutical formulation efforts

ANSWER: C

Rationale:

P-glycoprotein (encoded by the ABCB1 gene) is a member of the ATP-binding cassette (ABC) superfamily of active efflux transporters. It uses ATP hydrolysis to pump a wide variety of structurally diverse substrate drugs out of cells, opposing their passive absorption or tissue accumulation. At the intestinal epithelium, P-gp pumps absorbed drug back into the lumen, reducing net oral bioavailability — particularly for drugs that are both P-gp substrates and CYP3A4 substrates, since CYP3A4 and P-gp have overlapping substrate specificities and are co-expressed in enterocytes. At the blood-brain barrier, P-gp in endothelial cells pumps substrate drugs back into the bloodstream, sharply restricting CNS penetration — this is clinically exploited to keep some drugs out of the CNS, and a problem for CNS-targeted therapies whose substrates are pumped out before they reach their target. P-gp is inducible (by rifampin, St. John's wort) and inhibitable (by verapamil, cyclosporine, clarithromycin), creating important drug interactions. The interaction between digoxin (a P-gp substrate) and rifampin (a P-gp inducer) — causing reduced digoxin levels — and between digoxin and clarithromycin (a P-gp inhibitor) — causing elevated digoxin levels — are clinically well-documented examples.

5. Oral administration is the most common route of drug delivery. Which of the following factors most directly reduces the oral bioavailability of a drug?

A) Extensive hepatic first-pass metabolism, P-glycoprotein-mediated efflux in the intestinal wall, and poor aqueous solubility limiting dissolution in gut fluid — any of these alone, or in combination, can substantially reduce the fraction of an oral dose reaching systemic circulation
B) High molecular weight above 800 daltons, low plasma protein binding, and rapid renal excretion — these three factors together define the pharmacokinetic profile of drugs with poor oral bioavailability
C) High lipophilicity and low ionization at gastric pH — highly lipophilic drugs are trapped in the gut wall lipid bilayer and never released into portal blood, producing near-zero oral bioavailability for all drugs with logP above 3
D) Slow gastric emptying time — delayed gastric emptying is the single most important determinant of oral bioavailability for all drug classes because it extends the time drugs spend in the acidic stomach where absorption is negligible
E) Oral bioavailability is determined entirely by the drug's aqueous solubility — lipophilic drugs are always completely bioavailable orally because they are not subject to first-pass metabolism, while hydrophilic drugs always have poor bioavailability because they cannot dissolve in the intestinal fluid

ANSWER: A

Rationale:

Oral bioavailability is the net result of multiple sequential processes, any of which can limit the fraction of the administered dose that reaches systemic circulation. Poor aqueous solubility means the drug cannot dissolve adequately in gastrointestinal fluids — undissolved drug cannot be absorbed regardless of its membrane permeability. Intestinal wall efflux by P-glycoprotein pumps absorbed drug back into the gut lumen before it can enter portal blood. Intestinal wall metabolism by CYP3A4 (co-expressed with P-gp in enterocytes) degrades drug during the absorption process. And hepatic first-pass metabolism eliminates a further fraction of whatever reaches the portal circulation — for drugs with high hepatic extraction ratios this can reduce bioavailability to a small fraction of the absorbed dose. These factors are not mutually exclusive: a drug may suffer from both poor solubility and extensive first-pass metabolism simultaneously. Understanding which barrier is rate-limiting for a given drug is essential for rational formulation development and for anticipating drug interactions that alter bioavailability.

6. Nitroglycerin is used sublingually for acute angina rather than orally. Which pharmacokinetic principle best explains this route selection?

A) Sublingual administration increases the volume of distribution of nitroglycerin by delivering drug directly to the cardiac lymphatic circulation, bypassing the systemic venous system entirely
B) Oral nitroglycerin produces dose-dependent nephrotoxicity that is avoided by the sublingual route because renal blood flow is lower for drugs absorbed sublingually than for drugs absorbed from the gastrointestinal tract
C) Sublingual absorption delivers drug into the systemic venous circulation via the lingual veins, bypassing the portal circulation and hepatic first-pass metabolism — nitroglycerin undergoes extensive hepatic extraction and would have negligible oral bioavailability if swallowed
D) The sublingual route is selected because nitroglycerin is a weak base that is ionized at gastric pH and therefore cannot be absorbed from the stomach — sublingual pH is alkaline enough to maintain the drug in its un-ionized, absorbable form
E) Sublingual administration is preferred because the high vascularity of oral mucosa produces faster absorption than any other route, including intravenous injection, allowing nitroglycerin to reach the coronary arteries before hepatic metabolism can begin

ANSWER: C

Rationale:

Nitroglycerin is a highly lipophilic molecule with an extremely high hepatic extraction ratio — when swallowed and absorbed from the gastrointestinal tract, approximately 90-99% of the absorbed dose is metabolized during a single pass through the liver, leaving almost no active drug to reach the systemic circulation. The sublingual route circumvents this problem elegantly: the rich vascular supply of the sublingual mucosa allows rapid passive absorption directly into the systemic (not portal) venous circulation via the lingual and facial veins, which drain into the superior vena cava. Drug enters the systemic circulation without transiting the liver, preserving bioavailability. The onset of action is accordingly rapid — typically 1-2 minutes — making the sublingual route ideal for acute angina management. The same pharmacokinetic rationale applies to buccal, transdermal, and intravenous routes for nitroglycerin, all of which bypass portal circulation. This principle extends to other high-extraction drugs: it explains why oral morphine requires doses approximately 3 times higher than parenteral doses, and why some drugs simply cannot be administered orally at all.

7. A patient requires immediate achievement of therapeutic drug concentrations. Which of the following correctly describes the pharmacokinetic advantage of intravenous (IV) bolus administration over oral administration in this context?

A) IV administration produces higher peak plasma concentrations than oral administration of the same dose because IV drugs have larger volumes of distribution, concentrating drug in the plasma compartment rather than peripheral tissues
B) IV drugs bypass the volume of distribution entirely and act directly on target receptors in the bloodstream — this is why IV administration is limited to drugs whose molecular targets are located within the vascular compartment
C) IV administration is preferred in emergencies solely because oral medications cannot be given to unconscious patients — the pharmacokinetic profile of IV and oral drugs is otherwise identical once absorption is complete
D) IV bolus administration produces a sustained plateau in plasma concentration that persists for several hours without additional dosing, making it pharmacokinetically superior to oral dosing for all drugs regardless of half-life
E) IV administration achieves 100% bioavailability with immediate drug delivery to the systemic circulation, eliminating absorption lag time, first-pass metabolism, and bioavailability uncertainty — making it the preferred route when rapid, predictable, and complete drug delivery is clinically required

ANSWER: E

Rationale:

Intravenous bolus administration places drug directly into the systemic circulation, producing immediate and complete systemic exposure. Bioavailability is 100% by definition — no absorption step is required, no gastrointestinal barriers must be crossed, no first-pass hepatic metabolism occurs, and the uncertainty associated with variable oral absorption is eliminated. Plasma concentration rises instantaneously to its peak immediately after injection, then declines according to the drug's distribution and elimination kinetics. This combination of immediacy, completeness, and predictability makes IV administration the route of choice whenever therapeutic plasma concentrations must be achieved urgently — in acute seizures, status asthmaticus, anaphylaxis, cardiac arrest, and many critical care scenarios. The IV route also allows precise titration: infusion rate can be adjusted in real time to maintain target concentrations, something impossible with fixed oral doses. The trade-off is that errors are not retrievable — an IV dose that is too large cannot be un-given, and adverse effects must be managed as they arise.

8. Intramuscular (IM) and subcutaneous (SC) routes deliver drug into tissue rather than directly into the circulation. Which of the following correctly describes a pharmacokinetic feature that distinguishes these parenteral routes from IV administration?

A) IM and SC routes produce 100% bioavailability in all patients under all physiological conditions because bypassing the gastrointestinal tract eliminates all sources of bioavailability variability
B) IM and SC routes produce faster onset of action than IV administration for all drugs because tissue depots release drug in a concentrated bolus that reaches the heart before venous dilution can occur
C) IM and SC routes require an absorption step from the injection site into the capillary circulation — absorption rate depends on local blood flow, drug aqueous solubility, and formulation; in states of poor perfusion such as shock, absorption may be erratic or severely delayed
D) IM and SC routes are pharmacokinetically equivalent to oral administration because both require an absorption step before systemic drug delivery — the route of administration only matters if the drug is given intravenously
E) SC administration always produces slower absorption than IM administration because subcutaneous tissue has no blood supply and drug must diffuse passively through adipose tissue to reach capillaries, a process that takes several hours for most drugs

ANSWER: C

Rationale:

Intramuscular and subcutaneous routes deliver drug into tissue compartments that have a blood supply but are not part of the systemic circulation directly. Drug must traverse the interstitium and capillary wall to enter the bloodstream — this absorption step introduces pharmacokinetic variability not present with IV administration. The rate of absorption from these depots is governed primarily by local blood flow to the injection site. In shock, severe heart failure, or hypothermia, peripheral vasoconstriction markedly reduces tissue perfusion, slowing or halting absorption — a critical clinical consideration because a patient who receives IM epinephrine or morphine during circulatory collapse may absorb very little drug initially, only to absorb a large bolus later when perfusion is restored. Drug aqueous solubility also matters: highly lipophilic depot formulations (such as long-acting antipsychotics in oil) release drug slowly by design, while aqueous solutions are absorbed more rapidly. Bioavailability from IM and SC routes is high but not guaranteed at 100% for all drugs and formulations — variables including injection technique, site selection, and patient-specific factors all contribute.

9. Transdermal drug delivery systems are designed to deliver drug through the skin into the systemic circulation. Which of the following correctly identifies the primary pharmacokinetic advantage of the transdermal route for appropriate drugs?

A) Transdermal delivery achieves higher peak plasma concentrations than oral or IV administration because the skin acts as a drug reservoir that releases concentrated boluses into dermal capillaries at regular intervals
B) Transdermal delivery is universally applicable — any drug can be formulated as a transdermal patch regardless of physicochemical properties because skin permeability is determined by patch adhesion force rather than drug lipophilicity or molecular weight
C) Transdermal delivery is faster than IV administration for emergency indications because dermal capillaries deliver drug directly to the arterial circulation, bypassing the venous return and pulmonary circulation entirely
D) Transdermal delivery is most useful for hydrophilic high-molecular-weight drugs because the skin's aqueous surface layer selectively absorbs polar molecules and rejects lipophilic ones, making patches appropriate only for drugs that fail oral absorption due to poor lipophilicity
E) Transdermal delivery provides sustained systemic drug levels while bypassing hepatic first-pass metabolism and gastrointestinal degradation — it is best suited to potent lipophilic drugs with low molecular weight where the skin barrier can be traversed by passive diffusion

ANSWER: E

Rationale:

The stratum corneum — the outermost layer of the epidermis — is a formidable barrier composed of keratinized cells embedded in a lipid matrix. Passive drug diffusion through this barrier favors lipophilic, low-molecular-weight molecules for exactly the same reasons that apply to cell membrane permeation: the lipid matrix of the stratum corneum is traversed by un-ionized, lipophilic drugs far more readily than by polar or charged species. Once through the stratum corneum, drug enters the viable epidermis and dermis, which are richly vascularized, and is absorbed into the systemic venous circulation — bypassing gastrointestinal tract, gut wall metabolism, and hepatic first-pass extraction. The result is sustained, relatively constant plasma levels over hours to days (depending on patch design), which is pharmacokinetically advantageous for drugs requiring stable plasma concentrations. Classic transdermal drugs — nitroglycerin, fentanyl, scopolamine, nicotine, estradiol, clonidine — share the key properties: they are lipophilic, low molecular weight, and highly potent (since skin absorption rates limit the dose achievable per unit area).

10. Bioavailability (F) is formally defined and measured using plasma concentration-time data. Which of the following correctly states the formula for bioavailability and identifies what intravenous administration contributes to the measurement?

A) F = Cmax(oral) / Cmax(IV) for the same dose — intravenous administration provides the reference peak concentration because it is achieved without any absorption delay
B) F = AUC(route) / AUC(IV) for the same dose — intravenous administration defines the reference AUC representing 100% systemic exposure because drug is delivered directly into the systemic circulation with no absorption loss
C) F = t½(oral) / t½(IV) — intravenous administration provides the reference half-life, and oral bioavailability is expressed as the ratio of elimination half-lives because longer half-life indicates more complete absorption
D) F = Vd(oral) / Vd(IV) — the volume of distribution after oral dosing relative to IV dosing reflects how completely absorbed drug distributes into peripheral tissues, which determines the bioavailable fraction
E) F = CL(oral) / CL(IV) — intravenous clearance provides the reference because IV drug is fully exposed to all elimination pathways, and the ratio of clearance values reflects the fraction of the oral dose that survived first-pass extraction

ANSWER: B

Rationale:

Bioavailability is quantified by comparing the total systemic drug exposure achieved by the route of interest to the total systemic exposure achieved by intravenous administration of the same dose. Total systemic exposure is measured as the area under the plasma concentration-time curve (AUC), which integrates both the height (peak concentration) and the duration of drug presence in plasma — making it a more comprehensive measure of systemic availability than peak concentration alone. Intravenous administration is the universal reference because it delivers the entire dose directly into the systemic circulation with no absorption barrier, no first-pass metabolism, and no dissolution step — it defines 100% bioavailability by convention. If a 100 mg oral dose produces an AUC of 400 mg·h/L while a 100 mg IV dose produces an AUC of 1000 mg·h/L, the oral bioavailability is 40%. This value then informs dose adjustment: to achieve the same systemic exposure orally as intravenously, the oral dose must be increased by a factor of 1/F. The AUC ratio approach is the method used in regulatory bioequivalence studies to establish that a generic formulation delivers the same systemic exposure as the reference brand.

11. A drug has an oral bioavailability of 25%. A clinician wishes to switch a patient from IV to oral therapy while maintaining the same systemic drug exposure. Which of the following correctly describes the dose adjustment required?

A) The oral dose should be 25% of the IV dose because oral administration delivers drug more efficiently than IV by concentrating it in portal blood before systemic distribution
B) No dose adjustment is required — bioavailability affects peak concentration but not the total systemic exposure (AUC), so the same dose given orally produces equivalent therapeutic effect to the same dose given IV
C) The oral dose should be reduced to 12.5% of the IV dose to account for the combined effect of first-pass metabolism and gastrointestinal absorption losses, both of which reduce effective drug delivery by an additional 50% beyond the stated bioavailability figure
D) The oral dose should be four times the IV dose — if only 25% of the oral dose reaches systemic circulation, four times the dose must be administered orally to deliver the same amount of drug to the systemic circulation as the IV dose
E) The oral dose equals the IV dose multiplied by the square root of the bioavailability fraction — this mathematical relationship corrects for the non-linear absorption kinetics that characterize drugs with bioavailability below 50%

ANSWER: D

Rationale:

If a drug has a bioavailability of 25% (F = 0.25), then only 25 mg of every 100 mg oral dose reaches the systemic circulation. To deliver the same systemic amount as a 100 mg IV dose (which is 100% bioavailable), the oral dose must be: Oral Dose = IV Dose / F = 100 mg / 0.25 = 400 mg. This fourfold increase is necessary to compensate for the fraction lost to first-pass metabolism, intestinal wall metabolism, and incomplete absorption. The principle is expressed in the standard dose conversion formula: Oral Dose = Target systemic exposure / F. This same logic applies whenever a patient is transitioned between routes: switching from IV to oral requires an oral dose that is higher by a factor of 1/F, while switching from oral to IV requires reducing the dose by a factor of F to avoid toxicity from the suddenly complete bioavailability. For drugs with very low oral bioavailability (F < 0.10), the oral and IV doses may differ by an order of magnitude, which has obvious clinical and cost implications.

12. Grapefruit juice is known to increase the oral bioavailability of certain drugs, sometimes to a clinically dangerous degree. Which of the following correctly explains the pharmacokinetic mechanism?

A) Grapefruit juice raises gastric pH, converting weak acid drugs to their un-ionized form in the stomach and dramatically increasing passive absorption across the gastric epithelium — this applies to all orally administered drugs regardless of their metabolic pathway
B) Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal CYP3A4 — because CYP3A4 is responsible for significant first-pass metabolism of many drugs in enterocytes, its inhibition increases the fraction of the oral dose surviving to reach systemic circulation, raising AUC and peak concentrations
C) Grapefruit juice activates hepatic P-glycoprotein, increasing efflux of drugs from hepatocytes into bile — this reduces hepatic first-pass extraction and increases the systemic availability of drugs that are normally extensively extracted by the liver
D) Grapefruit juice inhibits gastric acid secretion, slowing dissolution of drug tablets and extending the absorption window — this increases total AUC for all orally administered solid dosage forms by prolonging the time drug remains in solution in the gastrointestinal tract
E) Grapefruit juice competes with drug binding sites on plasma albumin, displacing protein-bound drug and increasing the free fraction — this increases the apparent volume of distribution and reduces peak plasma concentrations of displaced drugs

ANSWER: B

Rationale:

Grapefruit juice contains naturally occurring furanocoumarins — particularly bergamottin and 6',7'-dihydroxybergamottin — that act as mechanism-based (irreversible) inhibitors of CYP3A4 in the small intestinal wall. Because the inhibition is mechanism-based, it persists for the lifetime of the affected enzyme molecules rather than clearing when the grapefruit juice is eliminated; a single glass of grapefruit juice can suppress intestinal CYP3A4 activity for 24-72 hours. CYP3A4 is co-expressed with P-glycoprotein in intestinal enterocytes and is responsible for substantial first-pass metabolism of many drugs during absorption. When CYP3A4 is inhibited, the fraction of the oral dose that survives intestinal wall metabolism increases, raising bioavailability and therefore AUC and peak concentrations — sometimes several-fold. Drugs particularly affected include calcium channel blockers (felodipine, nifedipine), statins (simvastatin, lovastatin), immunosuppressants (cyclosporine, tacrolimus), and some benzodiazepines. The clinical consequence can include severe hypotension, myopathy, or immunosuppressant toxicity. Note that grapefruit primarily inhibits intestinal, not hepatic, CYP3A4 because hepatic exposure to grapefruit juice constituents is limited by the concentrations that survive gut absorption.

13. A patient with severe liver cirrhosis is prescribed a drug that normally undergoes 85% hepatic first-pass extraction after oral administration. Compared to a patient with normal hepatic function receiving the same oral dose, what pharmacokinetic change is most likely in the cirrhotic patient?

A) The cirrhotic patient will have lower plasma drug concentrations than the normal patient because hepatic cirrhosis reduces intestinal motility, slowing absorption and reducing the total fraction of drug reaching the portal circulation
B) The cirrhotic patient will have unchanged plasma drug concentrations because the liver retains full metabolic capacity even in advanced cirrhosis — only biliary excretion, not drug metabolism, is impaired by hepatic fibrosis
C) The cirrhotic patient will have substantially higher plasma drug concentrations than the normal patient — reduced hepatic metabolic capacity lowers first-pass extraction, increasing the fraction of the oral dose reaching systemic circulation and raising AUC, sometimes to toxic levels
D) The cirrhotic patient will have lower peak plasma concentrations but a prolonged half-life compared to normal — the two effects cancel out mathematically so that the total AUC is unchanged and no dose adjustment is required
E) The cirrhotic patient will experience accelerated drug elimination because portal hypertension increases renal blood flow, compensating for reduced hepatic clearance by enhancing renal drug excretion proportionally

ANSWER: C

Rationale:

Hepatic cirrhosis impairs first-pass metabolism through two complementary mechanisms. First, hepatocellular damage and loss of functional hepatocyte mass directly reduce the metabolic capacity of the liver, meaning less drug is biotransformed per unit time. Second, intrahepatic shunting of portal blood through fibrotic tissue and portosystemic collateral vessels means that a fraction of portal blood bypasses functioning hepatocytes entirely, reducing effective hepatic extraction even further. For a drug with 85% normal first-pass extraction, the oral bioavailability in a normal patient is approximately 15% — meaning 85 mg of every 100 mg oral dose is destroyed before reaching systemic circulation. In cirrhosis, if first-pass extraction falls to 40%, bioavailability rises to 60% — a fourfold increase in systemic exposure from the same oral dose. This is clinically dangerous for drugs with narrow therapeutic indices that are highly extracted by the liver. Classic examples include opioids (morphine, meperidine), beta-blockers (propranolol), and some benzodiazepines, where standard oral doses in cirrhotic patients can produce profound toxicity. Dose reduction is mandatory for high-extraction drugs in patients with significant hepatic impairment.

14. Two drug formulations of the same active compound are described as bioequivalent by regulatory standards. Which of the following correctly defines bioequivalence and its clinical significance?

A) Two formulations are bioequivalent if they contain identical amounts of active ingredient — bioequivalence is established by label comparison alone without the need for pharmacokinetic studies in human subjects
B) Two formulations are bioequivalent if they produce the same maximum plasma concentration (Cmax) after oral administration, regardless of differences in AUC or time to peak concentration — AUC equivalence is not required for regulatory approval of generic drugs
C) Two formulations are bioequivalent if the 90% confidence intervals for the ratios of their AUC and Cmax values fall within the regulatory acceptance range of 80-125% when tested in human subjects under standardized conditions — this standard ensures that a generic formulation delivers statistically equivalent systemic exposure to the reference product
D) Two formulations are bioequivalent if they produce equivalent clinical outcomes in randomized controlled trials — pharmacokinetic data from plasma sampling are insufficient to establish bioequivalence without clinical endpoint confirmation for each drug class
E) Two formulations are bioequivalent if they contain the same active ingredient and are manufactured under identical Good Manufacturing Practice conditions — the manufacturing process is the sole determinant of bioequivalence under current FDA guidelines

ANSWER: C

Rationale:

Regulatory bioequivalence is established through pharmacokinetic studies in human subjects that compare the systemic exposure profiles of the test and reference formulations. The standard requires that the 90% confidence intervals for the geometric mean ratios of AUC (total exposure) and Cmax (peak exposure) fall within the 80-125% acceptance window. This framework acknowledges that some variability between formulations is acceptable while ensuring that clinically meaningful differences in exposure are excluded. The 80-125% window was derived from pharmacodynamic modeling demonstrating that differences within this range are unlikely to produce clinically detectable differences in efficacy or safety for most drugs. Additional parameters — time to peak concentration (Tmax) — are also examined, particularly for modified-release formulations. Bioequivalence studies allow regulatory approval of generic drugs without repeating the full clinical trial program of the reference product, provided pharmaceutical equivalence (same active ingredient, dose, and dosage form) is confirmed and bioequivalence is demonstrated. For drugs with narrow therapeutic indices (e.g., warfarin, phenytoin, levothyroxine), the FDA applies additional scrutiny and some jurisdictions require additional bioequivalence data because the 80-125% window may be too wide for safety.

15. A prescriber switches a patient from oral morphine 30 mg every 4 hours to IV morphine for post-operative pain management. Oral morphine has a bioavailability of approximately 30-40%. Which of the following best describes the pharmacokinetic rationale for the dose adjustment required at this transition?

A) The IV dose should be increased threefold relative to the oral dose because intravenous administration distributes drug more widely throughout peripheral tissues, requiring more drug to achieve the same plasma concentration as the oral route
B) No dose adjustment is required when switching between oral and IV morphine — bioavailability differences are offset by faster IV distribution, so the therapeutic plasma concentration achieved is the same for equivalent oral and IV doses
C) The IV dose should be increased to account for the loss of first-pass metabolism — because IV morphine bypasses the liver entirely, more morphine-6-glucuronide (the active metabolite) is produced peripherally and a higher IV dose is needed to generate equivalent analgesia
D) The IV dose should be reduced to approximately one-third of the oral dose — intravenous administration delivers 100% of the dose to the systemic circulation, so the same systemic exposure achieved by 30 mg oral (approximately 9-12 mg systemically available) requires only approximately 10 mg IV
E) The IV dose should equal the oral dose divided by the square of the bioavailability fraction — for morphine with F = 0.33, the IV dose equals 30 mg / (0.33)² ≈ 275 mg, reflecting the exponential relationship between route and systemic exposure

ANSWER: D

Rationale:

This question applies the bioavailability conversion formula to a clinically common and high-stakes transition. Morphine has approximately 30-40% oral bioavailability, reflecting extensive hepatic first-pass metabolism — CYP2D6 converts morphine to active morphine-6-glucuronide and inactive morphine-3-glucuronide, while significant parent drug is also eliminated. When 30 mg of oral morphine is administered, approximately 9-12 mg of equivalent drug activity reaches the systemic circulation. Intravenous administration delivers the full dose systemically — 100% bioavailability. To achieve equivalent systemic exposure by the IV route, the dose is calculated as: IV dose = Oral dose × F = 30 mg × 0.33 ≈ 10 mg. In practice, opioid equianalgesic conversion tables use an oral-to-IV ratio of approximately 3:1 for morphine (30 mg oral ≈ 10 mg IV), which reflects this bioavailability relationship. Failure to reduce the dose when transitioning from oral to IV is a well-documented cause of opioid overdose in clinical settings — an error with potentially fatal consequences. The same principle applies to any route transition for a drug with substantial first-pass metabolism: the IV dose is always lower than the oral dose by the factor F.

BEFORE YOU MOVE ON

You have worked through 15 questions covering the pharmacokinetic determinants of drug absorption and bioavailability — membrane physiology and passive diffusion, ionization and the Henderson-Hasselbalch principle, transporter-mediated absorption and efflux, route-specific pharmacokinetic profiles, first-pass hepatic extraction, AUC-based bioavailability calculation, the grapefruit-CYP3A4 interaction mechanism, bioequivalence standards, and route conversion calculations. These principles explain why the same drug given by different routes requires different doses, why some drugs cannot be given orally, and why hepatic disease dramatically alters systemic exposure. Module 2 builds directly on this framework by examining what happens to drug once it enters the systemic circulation — how it distributes into tissues and binds to proteins.